On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Please provide your email address to receive an email when new articles are posted on . Continued anticoagulation is recommended for patients with active cancer and/or ongoing cancer treatment.

or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of ...

One group received standard care, while the other got standard care plus apixaban (2.5 mg twice daily) for three months. After three months, the apixaban group had fewer clot recurrences—24% ...

The anticlotting drug, Eliquis, has been approved for use in the United States by the country’s regulatory body, the Food and Drug Administration (FDA). Eliquis is manufactured by Bristol-Myers ...